BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El-miligy MM, Abd El Razik HA, Abu-serie MM. Synthesis of piperazine-based thiazolidinones as VEGFR2 tyrosine kinase inhibitors inducing apoptosis. Future Medicinal Chemistry 2017;9:1709-29. [DOI: 10.4155/fmc-2017-0072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Eldehna WM, Maklad RM, Almahli H, Al-Warhi T, Elkaeed EB, Abourehab MAS, Abdel-Aziz HA, El Kerdawy AM. Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights. J Enzyme Inhib Med Chem 2022;37:1227-40. [PMID: 35470754 DOI: 10.1080/14756366.2022.2062337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Al-ghorbani M, Gouda MA, Baashen M, Alharbi O, Almalki FA, Ranganatha LV. Piperazine Heterocycles as Potential Anticancer Agents: A Review. Pharm Chem J. [DOI: 10.1007/s11094-022-02597-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wang C, Zhang Y, Wang J, Xing D. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. Eur J Med Chem 2022;227:113906. [PMID: 34656901 DOI: 10.1016/j.ejmech.2021.113906] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
4 Shawky AM, Abourehab MA, Abdalla AN, Gouda AM. Optimization of pyrrolizine-based Schiff bases with 4-thiazolidinone motif: Design, synthesis and investigation of cytotoxicity and anti-inflammatory potency. European Journal of Medicinal Chemistry 2020;185:111780. [DOI: 10.1016/j.ejmech.2019.111780] [Cited by in Crossref: 14] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
5 Yang Z, Gu JM, Ma QY, Xue N, Shi XW, Wang L, Zhang K, Wang YB, Cao DY, Guo R, Xing RJ. Design, synthesis and antitumor activity of aromatic urea-quinazolines. Future Med Chem 2019;11:2821-30. [PMID: 31510797 DOI: 10.4155/fmc-2019-0220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ayati A, Emami S, Moghimi S, Foroumadi A. Thiazole in the targeted anticancer drug discovery. Future Medicinal Chemistry 2019;11:1929-52. [DOI: 10.4155/fmc-2018-0416] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 8.7] [Reference Citation Analysis]
7 Evren AE, Yurttaş L, Eksellı B, Akalın-cıftcı G. Novel Tri-substituted Thiazoles Bearing Piperazine Ring: Synthesis and Evaluation of their Anticancer Activity. LDDD 2019;16:547-55. [DOI: 10.2174/1570180815666180731122118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Shaaban OG, Abd El Razik HA, A Shams El-Dine SE, Ashour FA, El-Tombary AA, Afifi OS, Abu-Serie MM. Purines and triazolo[4,3-e]purines containing pyrazole moiety as potential anticancer and antioxidant agents. Future Med Chem 2018;10:1449-64. [PMID: 29788781 DOI: 10.4155/fmc-2017-0227] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
9 Uversky VN, El-Fakharany EM, Abu-Serie MM, Almehdar HA, Redwan EM. Divergent Anticancer Activity of Free and Formulated Camel Milk α-Lactalbumin. Cancer Invest 2017;35:610-23. [PMID: 28949782 DOI: 10.1080/07357907.2017.1373783] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]